REFERENCES
- Hwang NS, Zhang C, Hwang YS, Mesenchymal stem cell differentiation and roles in regenerative medicine. Wiley Interdiscip Rev Syst Biol Med. 2009;1:97–106.
- Arnhold S, Heiduschka P, Klein H, Adenovirally transduced bone marrow stromal cells differentiate into pigment epithelial cells and induce rescue effects in RCS rats. Invest Ophthalmol Vis Sci. 2006;47:4121–4129.
- Oswald J, Boxberger S, Jorgensen B, Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells. 2004;22:377–384.
- Hocking AM, Gibran NS. Mesenchymal stem cells: paracrine signaling and differentiation during cutaneous wound repair. Exp Cell Res. 2010;316:2213–2219.
- Lee RH, Pulin AA, Seo MJ, Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5:54–63.
- Liotta F, Angeli R, Cosmi L, Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells. 2008;26:279–289.
- Dimmeler S, Burchfield J, Zeiher AM. Cell-based therapy of myocardial infarction. Arterioscler Thromb Vasc Biol. 2008;28:208–216.
- Ott HC, McCue J, Taylor DA. Cell-based cardiovascular repair–the hurdles and the opportunities. Basic Res Cardiol. 2005;100:504–517.
- Sherman W, Martens TP, Viles-Gonzalez JF, Catheter-based delivery of cells to the heart. Nat Clin Pract Cardiovasc Med. 2006;3 (Suppl 1):S57–S64.
- Abdel-Mageed AS, Senagore AJ, Pietryga DW, Intravenous administration of mesenchymal stem cells genetically modified with extracellular superoxide dismutase improves survival in irradiated mice. Blood. 2009;113:1201–1203.
- Lazarus HM, Haynesworth SE, Gerson SL, Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant. 1995;16:557–564.
- Horwitz EM, Prockop DJ, Fitzpatrick LA, Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999;5:309–313.
- Le Blanc K, Frassoni F, Ball L, Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579–1586.
- Wu KH, Chan CK, Tsai C, Effective treatment of severe steroid-resistant acute graft-versus-host disease with umbilical cord-derived mesenchymal stem cells. Transplantation. 2011;91:1412–1416.
- Schrepfer S, Deuse T, Reichenspurner H, Stem cell transplantation: the lung barrier. Transplant Proc. 2007;39:573–576.
- Fischer UM, Harting MT, Jimenez F, Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009;18:683–692.
- Ramot Y, Steiner M, Morad V, Pulmonary thrombosis in the mouse following intravenous administration of quantum dot-labeled mesenchymal cells. Nanotoxicology. 2010;4:98–105.
- Furlani D, Ugurlucan M, Ong L, Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy. Microvasc Res. 2009;77:370–376.
- Hall B, Andreeff M, Marini F. The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb Exp Pharmacol. 2007;180:263–283.
- Nanbo T. A method to inject the umbilical vein of the rat. Reprod Toxicol. 1990;4:203–208.
- Nasu T, Arishima K. Development of the ductus venosus in the SD rat. Fukuoka Igaku Zasshi. 2004;95:9–16.
- Ozer EA, Yilmaz O, Akhisaroqu M, Heat shock protein 70 expression in neonatal rats after hypoxic stress. J Matern Fetal Neonatal Med. 2002;12:112–117.
- Pillai SB, Luquette MH, Nowicki PT, Segmental intestinal ischemia: an improved method of producing small bowel injury. J Invest Surg. 1998;11:123–128.
- Xia G, Rachfal AW, Martin AE, Upregulation of endogenous heparin-binding EGF-like growth factor (HB-EGF) expression after intestinal ischemia/reperfusion injury. J Invest Surg. 2003;16:57–63.
- Graham ML, Mutch LA, Rieke EF, Long-term heptic vascular access in the nonhuman primate for recurrent portal vein infusion. J Invest Surg. 2011;24:59–66.
- Kliegman RM, Fanaroff AA. Necrotizing enterocolitis. N Engl J Med. 1984;310:1093–1103.
- Yu X, Radulescu A, Zorko N, Heparin-binding EGF-like growth factor increases intestinal microvascular blood flow in necrotizing enterocolitis. Gastroenterology. 2009;137:221–230.
- Feng J, El-Assal ON, Besner GE. Heparin-binding epidermal growth factor-like growth factor decreases the incidence of necrotizing enterocolitis in neonatal rats. J Pediatr Surg. 2006;41:144–149; discussion 144–149.
- Feng J, El-Assal ON, Besner GE. Heparin-binding epidermal growth factor-like growth factor reduces intestinal apoptosis in neonatal rats with necrotizing enterocolitis. J Pediatr Surg. 2006;41:742–747; discussion 742–747.
- Feng J, Besner GE. Heparin-binding epidermal growth factor-like growth factor promotes enterocyte migration and proliferation in neonatal rats with necrotizing enterocolitis. J Pediatr Surg. 2007;42:214–220.
- Ankrum J, Karp JM. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med. 2010;16:203–209.